Triple negative breast cancer: unmet medical needs.

Abstract:

:Triple negative breast cancer (TNBC) is an aggressive clinical phenotype characterized by lack of expression (or minimal expression) of estrogen receptor (ER) and progesterone receptor (PR) as well as an absence of human epidermal growth factor receptor-2 (HER2) overexpression. It shows substantial overlap with basal-type and BRCA1-related breast cancers, both of which also have aggressive clinical courses. However, this overlap is not complete, and the expression of ER, PR, and HER2 has been noted in basal-like tumors. TNBC also includes the normal-like subtype, and not all patients with TNBC harbor BRCA1 mutations. Because of its expression profile, TNBC is not amenable to treatment with hormone therapy or the anti-HER2 monoclonal antibody trastuzumab, and systemic treatment options are currently limited to cytotoxic chemotherapy. Overall survival, whether in early-stage or advanced disease, is poor compared with that in patients who have other phenotypes. A number of targeted approaches to TNBC are undergoing clinical evaluation, including the use of agents with poly(ADP-ribose) polymerase inhibitory properties such as iniparib (the United States Adopted Name for the investigational agent BSI-201), olaparib (AZD2281), and veliparib (ABT-888), antiangiogenic agents such as bevacizumab and sunitinib, and epidermal growth factor receptor blockers such as cetuximab and erlotinib. Encouraging results with some of these agents have been reported, thereby offering the promise for improved outcomes in patients with TNBC. The clinical characteristics of TNBC and clinical experience to date with novel targeted agents under development for this aggressive phenotype is reviewed.

authors

Pal SK,Childs BH,Pegram M

doi

10.1007/s10549-010-1293-1

subject

Has Abstract

pub_date

2011-02-01 00:00:00

pages

627-36

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

125

pub_type

杂志文章,评审
  • Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts.

    abstract:BACKGROUND:Three tools are currently available to predict the risk of contralateral breast cancer (CBC). We aimed to compare the performance of the Manchester formula, CBCrisk, and PredictCBC in patients with invasive breast cancer (BC). METHODS:We analyzed data of 132,756 patients (4682 CBC) from 20 international stu...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05611-8

    authors: Giardiello D,Hauptmann M,Steyerberg EW,Adank MA,Akdeniz D,Blom JC,Blomqvist C,Bojesen SE,Bolla MK,Brinkhuis M,Chang-Claude J,Czene K,Devilee P,Dunning AM,Easton DF,Eccles DM,Fasching PA,Figueroa J,Flyger H,García-Cl

    更新日期:2020-06-01 00:00:00

  • Double reading of diffusion-weighted magnetic resonance imaging for breast cancer detection.

    abstract:PURPOSE:To estimate the performance of diffusion-weighted imaging (DWI) for breast cancer detection. METHODS:Consecutive breast magnetic resonance imaging examinations performed from January to September 2016 were retrospectively evaluated. Examinations performed before/after neoadjuvant therapy, lacking DWI sequences...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05519-y

    authors: Rotili A,Trimboli RM,Penco S,Pesapane F,Tantrige P,Cassano E,Sardanelli F

    更新日期:2020-02-01 00:00:00

  • Plasma carotenoids and the risk of premalignant breast disease in women aged 50 and younger: a nested case-control study.

    abstract:PURPOSE:To examine the association of plasma carotenoids, micronutrients in fruits, and vegetables, with risk of premalignant breast disease (PBD) in younger women. METHODS:Blood samples were collected at the Siteman Cancer Center between 2008 and 2012 from 3537 women aged 50 or younger with no history of cancer or PB...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4152-5

    authors: Cohen K,Liu Y,Luo J,Appleton CM,Colditz GA

    更新日期:2017-04-01 00:00:00

  • A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer.

    abstract::To date, three molecular markers (ER, PR, and CYP2D6) have been used in clinical setting to predict the benefit of the anti-estrogen tamoxifen therapy. Our aim was to validate new biomarker candidates predicting response to tamoxifen treatment in breast cancer by evaluating these in a meta-analysis of available transc...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-013-2622-y

    authors: Mihály Z,Kormos M,Lánczky A,Dank M,Budczies J,Szász MA,Győrffy B

    更新日期:2013-07-01 00:00:00

  • Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast.

    abstract::Following mastectomy, patients with operable breast cancer underwent postoperative irradiation of the chest wall and regional lymph nodes. They were then assigned at random to receive no further therapy, ovarian irradiation (2000 rad in five days) or ovarian irradiation in the same dosage plus prednisone, 7.5 mg daily...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF01855127

    authors: Meakin JW,Allt WE,Beale FA,Bush RS,Clark RM,Fitzpatrick PJ,Hawkins NV,Jenkin RD,Pringle JF,Reid JG

    更新日期:1983-01-01 00:00:00

  • Mammographic breast density decreases after bariatric surgery.

    abstract:PURPOSE:Breast density (BD), an important risk factor for breast cancer, can change over time in some women, but the underlying mechanism is unclear. Very little is known about the impact of surgical weight loss on BD. Our hypothesis is that weight loss after bariatric surgery is associated with a significant and favor...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4361-y

    authors: Williams AD,So A,Synnestvedt M,Tewksbury CM,Kontos D,Hsiehm MK,Pantalone L,Conant EF,Schnall M,Dumon K,Williams N,Tchou J

    更新日期:2017-10-01 00:00:00

  • Management of brain metastases in breast cancer: a review of current practices and emerging treatments.

    abstract:PURPOSE:Breast cancer brain metastases (BCBM) are becoming an increasingly common diagnosis due to improved systemic control and more routine surveillance imaging. Treatment continues to require a multidisciplinary approach managing systemic and intracranial disease burden. Although, improvements have been made in the ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-020-05552-2

    authors: Mills MN,Figura NB,Arrington JA,Yu HM,Etame AB,Vogelbaum MA,Soliman H,Czerniecki BJ,Forsyth PA,Han HS,Ahmed KA

    更新日期:2020-04-01 00:00:00

  • CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.

    abstract::Overexpression of CD24 is an independent prognostic factor for breast cancer. Recently, two polymorphisms in the CD24 gene were linked to disease risk and progression in autoimmune diseases. Here, we evaluated the clinical relevance of these polymorphisms with respect to their potential to predict a pathologic complet...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-011-1759-9

    authors: Marmé F,Werft W,Walter A,Keller S,Wang X,Benner A,Burwinkel B,Sinn P,Hug S,Sohn C,Bretz N,Moldenhauer G,Rupp C,Rupp AK,Biakhov MY,Bottini A,Friedrichs K,Khailenko VA,Manikhas GM,Ruiz A,Sánchez-Rovira P,Santoro A

    更新日期:2012-04-01 00:00:00

  • mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.

    abstract::Resistance of breast cancers to targeted hormone receptor (HR) or human epidermal growth factor receptor 2 (HER2) inhibitors often occurs through dysregulation of the phosphoinositide 3-kinase, protein kinase B/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway. Presently, no targeted therapies exist for breast...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-2877-y

    authors: Wilson-Edell KA,Yevtushenko MA,Rothschild DE,Rogers AN,Benz CC

    更新日期:2014-04-01 00:00:00

  • Differences in breast cancer incidence among young women aged 20-49 years by stage and tumor characteristics, age, race, and ethnicity, 2004-2013.

    abstract:PURPOSE:Younger women diagnosed with breast cancer have poorer prognoses and higher mortality compared to older women. Young black women have higher incidence rates of breast cancer and more aggressive subtypes than women of other races/ethnicities. In this study, we examined recent trends and variations in breast canc...

    journal_title:Breast cancer research and treatment

    pub_type: 历史文章,杂志文章

    doi:10.1007/s10549-018-4699-9

    authors: Shoemaker ML,White MC,Wu M,Weir HK,Romieu I

    更新日期:2018-06-01 00:00:00

  • Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study.

    abstract::Estrogen receptor (ER)-positive/progesterone receptor (PR)-positive invasive ductal carcinoma accounts for ~45 % of invasive breast cancer (BC) diagnoses in the U.S. Despite reductions in BC mortality attributable to mammography screening and adjuvant hormonal therapy, an important challenge remains the development of...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3554-5

    authors: Buas MF,Rho JH,Chai X,Zhang Y,Lampe PD,Li CI

    更新日期:2015-09-01 00:00:00

  • Analyses of microsatellite instability and the transforming growth factor-beta receptor type II gene mutation in sporadic breast cancer and their correlation with clinicopathological features.

    abstract::To determine the incidence of microsatellite instability (MSI) and its relationship with both clinicopathologic parameters and patient survival, 101 cases of breast cancer were investigated. In addition, transforming growth factor-beta (TGF-beta) receptor type II (RII) gene mutation was also examined to clarify the re...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006167210269

    authors: Tomita S,Deguchi S,Miyaguni T,Muto Y,Tamamoto T,Toda T

    更新日期:1999-01-01 00:00:00

  • Medical costs associated with metastatic breast cancer in younger, midlife, and older women.

    abstract:PURPOSE:We estimated average medical costs due to metastatic breast cancer (mBC) among younger (aged 18-44), midlife (aged 45-64), and older women (aged 65 and older) by phase of care: initial, continuing, and terminal. METHODS:We used 2003-2014 North Carolina cancer registry data linked with administrative claims fro...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05654-x

    authors: Trogdon JG,Baggett CD,Gogate A,Reeder-Hayes KE,Rotter J,Zhou X,Ekwueme DU,Fairley TL,Wheeler SB

    更新日期:2020-06-01 00:00:00

  • Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease.

    abstract:PURPOSE:Women with benign breast disease (BBD) have an increased risk of subsequent breast cancer. However, whether conventional breast cancer risk factors influence risk of breast cancer among women with BBD is unclear. In this study, we investigated the associations of lifestyle, menstrual/reproductive, and histologi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4347-9

    authors: Arthur R,Wang Y,Ye K,Glass AG,Ginsberg M,Loudig O,Rohan T

    更新日期:2017-10-01 00:00:00

  • Four cases of chylous fistula after breast cancer resection.

    abstract::Chylous fistulas in cases treated surgically for breast cancer only, are rare. We encountered four chylous fistula cases after breast cancer operations out of a total of 851 cases, all of which involved the left breast. Chylous fistulas were confirmed by axillary white fluid and were unrelated to obesity, surgical met...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/B:BREA.0000010675.87358.b6

    authors: Nakajima E,Iwata H,Iwase T,Murai H,Mizutani M,Miura S,Kato H

    更新日期:2004-01-01 00:00:00

  • Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment.

    abstract::The aim of this study is to evaluate the impact of CYP2D6 genotyping in predicting disease-free survival and toxicity in breast cancer patients treated with adjuvant tamoxifen. DNA from 91 patients was genotyped using the AmpliChip CYP450 GeneChip, Roche that facilitates the classification of individuals by testing 27...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0328-y

    authors: Ramón y Cajal T,Altés A,Paré L,del Rio E,Alonso C,Barnadas A,Baiget M

    更新日期:2010-01-01 00:00:00

  • Follow-up cost of breast cancer patients with localized disease after primary treatment: a randomized trial.

    abstract::We studied the cost of follow-up of 472 breast cancer patients without distant metastasis after primary treatment in four different schedules in a randomized trial. The mean follow-up was 4.2 years. The four schedules differed in frequency of follow-up visits (every third or sixth month) and in intensity of diagnostic...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-005-5199-2

    authors: Kokko R,Hakama M,Holli K

    更新日期:2005-10-01 00:00:00

  • Transcriptional profiles of progestogen effects in the postmenopausal breast.

    abstract::Estrogen plus progestin hormone therapy has been associated with increased breast proliferation, breast density, and breast cancer risk in postmenopausal women, beyond that seen with estrogen alone. The goal of this study was to evaluate progestogen effects on gene expression profiles in the breast contributing to thi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-0003-8

    authors: Wood CE,Register TC,Cline JM

    更新日期:2009-03-01 00:00:00

  • Racial disparities in survival outcomes among breast cancer patients by molecular subtypes.

    abstract:PURPOSE:Differences in tumor biology, genomic architecture, and health care delivery patterns contribute to the breast cancer mortality gap between White and Black patients in the US. Although this gap has been well documented in previous literature, it remains uncertain how large the actual effect size of race is for ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05984-w

    authors: Zhao F,Copley B,Niu Q,Liu F,Johnson JA,Sutton T,Khramtsova G,Sveen E,Yoshimatsu TF,Zheng Y,Ibraheem A,Jaskowiak N,Nanda R,Fleming GF,Olopade OI,Huo D

    更新日期:2020-10-27 00:00:00

  • Receipt of locoregional therapy among young women with breast cancer.

    abstract::Although younger women with breast cancer have the most to gain from receipt of optimal care, few data are available regarding their receipt of locoregional breast cancer treatments. We identified 317,596 women aged 18-64 who were diagnosed with invasive breast cancer at hospitals reporting to the National Cancer Data...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2156-8

    authors: Freedman RA,Virgo KS,Labadie J,He Y,Partridge AH,Keating NL

    更新日期:2012-10-01 00:00:00

  • Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.

    abstract::Docetaxel is primarily metabolized by CYP3A4 and susceptible to alterations in clearance by CYP3A4 inhibition and induction. Imatinib is a CYP3A4 inhibitor. A phase I study of docetaxel and imatinib in metastatic breast cancer (MBC) was conducted to test the hypothesis that imatinib decreased docetaxel clearance. Doce...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1413-6

    authors: Connolly RM,Rudek MA,Garrett-Mayer E,Jeter SC,Donehower MG,Wright LA,Zhao M,Fetting JH,Emens LA,Stearns V,Davidson NE,Baker SD,Wolff AC

    更新日期:2011-05-01 00:00:00

  • Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer.

    abstract:PURPOSE:Chemotherapy-induced amenorrhea (CIA) by newer taxane-containing regimens was evaluated in early breast cancer (EBC) patients. METHODS:A prospective cohort of 122 premenopausal EBC patients participated in a phase III trial of preoperative docetaxel/capecitabine (TX) versus doxorubicin/cyclophosphamide (AC); 3...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-008-0071-9

    authors: Han HS,Ro J,Lee KS,Nam BH,Seo JA,Lee DH,Lee H,Lee ES,Kang HS,Kim SW

    更新日期:2009-05-01 00:00:00

  • Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases.

    abstract::Conflicting theories of epithelial carcinogenesis disagree on the clonal composition of primary tumors and on the time at which metastases occur. In order to study the spatial distribution of disparate clonal populations within breast carcinomas and the extent of the genetic relationship between primary tumors and reg...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9317-6

    authors: Torres L,Ribeiro FR,Pandis N,Andersen JA,Heim S,Teixeira MR

    更新日期:2007-04-01 00:00:00

  • Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.

    abstract::Inflammatory breast cancer (IBC) is a rare and aggressive disease. Previous studies have shown that among patients with stage III breast cancer, IBC is associated with a worse prognosis than noninflammatory breast cancer (non-IBC). Whether this difference holds true among patients with stage IV breast cancer has not b...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3436-x

    authors: Fouad TM,Kogawa T,Liu DD,Shen Y,Masuda H,El-Zein R,Woodward WA,Chavez-MacGregor M,Alvarez RH,Arun B,Lucci A,Krishnamurthy S,Babiera G,Buchholz TA,Valero V,Ueno NT

    更新日期:2015-07-01 00:00:00

  • Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer.

    abstract:PURPOSE:The epithelial-mesenchymal transition (EMT) plays a key role in breast cancer progression and metastasis. Lipocalin 2 (LCN2) is involved in the regulation of EMT. The aim of this study was to investigate the clinicopathological significance of LCN2 expression in breast cancer. METHODS:The expression of LCN2 pr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05488-2

    authors: Kurozumi S,Alsaeed S,Orah N,Miligy IM,Joseph C,Aljohani A,Toss MS,Fujii T,Shirabe K,Green AR,Aleskandarany MA,Rakha EA

    更新日期:2020-02-01 00:00:00

  • Lactandrate: a D-homo-aza-androsterone alkylator in the treatment of breast cancer.

    abstract::The sensitivity of breast neoplasms to hormonal control provides the basis of novel investigational treatments with steroidal alkylators. An androsterone D-lactam steroidal ester, the 3beta-hydroxy-13alpha-amino-13,17-seco- 5alpha-androstan-17-oic-13,17-lactam, p-bis(2-chloroethyl)amino phenyl acetate (lactandrate) wa...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-9083-x

    authors: Trafalis DT,Geromichalos GD,Koukoulitsa C,Papageorgiou A,Karamanakos P,Camoutsis C

    更新日期:2006-05-01 00:00:00

  • Knowledge and perceptions of familial and genetic risks for breast cancer risk in adolescent girls.

    abstract::Evidence suggests early events might modify adult breast cancer risk and many adolescents learn of familial and genetic risks for breast cancer. Little is known about how adolescent girls understand and respond to breast cancer risk. Semi-structured interviews with 11-19 year-old girls at high-risk and population-risk...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-012-2254-7

    authors: Bradbury AR,Patrick-Miller L,Egleston BL,Schwartz LA,Sands CB,Shorter R,Moore CW,Tuchman L,Rauch P,Malhotra S,Rowan B,Van Decker S,Schmidheiser H,Bealin L,Sicilia P,Daly MB

    更新日期:2012-12-01 00:00:00

  • Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.

    abstract::Fulvestrant fIRst-line Study comparing endocrine Treatments is a phase II, randomized, open-label study comparing fulvestrant 500 mg with anastrozole 1 mg as first-line endocrine therapy for postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer. At data cut-off, only 36 % of patients had pro...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/s10549-012-2192-4

    authors: Robertson JF,Lindemann JP,Llombart-Cussac A,Rolski J,Feltl D,Dewar J,Emerson L,Dean A,Ellis MJ

    更新日期:2012-11-01 00:00:00

  • Estrone sulfate: a potential source of estradiol in human breast cancer tissues.

    abstract::Local formation of estradiol in human breast tumors could provide a more important source of estrogen than is delivered from plasma. Prior studies have suggested that estrone is primarily synthesized from estrone sulfate. The enzyme 17 beta-hydroxysteroid dehydrogenase (HSD) would be required to convert estrone to est...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01886734

    authors: Santner SJ,Leszczynski D,Wright C,Manni A,Feil PD,Santen RJ

    更新日期:1986-01-01 00:00:00

  • Rho proteins and cancer.

    abstract::The Rho family of GTPases has been intensively studied for their roles in signal transduction processes leading to cytoskeletal-dependent responses, including cell migration and phagocytosis. In addition, they are important regulators of cell cycle progression and affect the expression of a number of genes, including ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/B:BREA.0000018423.47497.c6

    authors: Ridley AJ

    更新日期:2004-03-01 00:00:00